Trial Profile
COVID-19: A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Sep 2023
Price :
$35
*
At a glance
- Drugs Ad26.COV2 S (Primary) ; Influenza vaccine quadrivalent Seqirus (Primary) ; Influenza virus vaccine (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics; Registrational
- Sponsors Janssen Vaccines and Prevention B.V
- 20 Dec 2022 Status changed from active, no longer recruiting to completed.
- 22 Nov 2022 Planned End Date changed from 3 Nov 2022 to 15 Nov 2022.
- 25 Oct 2022 Status changed from recruiting to active, no longer recruiting.